{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:48Z","timestamp":1787161008848,"version":"build-2736575974"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"crossref","award":["41086"],"award-info":[{"award-number":["41086"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10549-020-05954-2","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T14:02:38Z","timestamp":1601733758000},"page":"261-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Immune microenvironment in different molecular subtypes of ductal breast carcinoma"],"prefix":"10.1007","volume":"185","author":[{"given":"Mona","family":"Sadeghalvad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid-Reza","family":"Mohammadi-Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,3]]},"reference":[{"key":"5954_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69:7\u201334","journal-title":"CA Cancer J Clin"},{"key":"5954_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/his.14091","author":"P Hoon Tan","year":"2020","unstructured":"Hoon Tan P, Ellis I, Allison K, Brogi E et al (2020) The 2019 WHO classification of tumours of the breast. Histopathology. https:\/\/doi.org\/10.1111\/his.14091","journal-title":"Histopathology"},{"key":"5954_CR3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41379-019-0204-1","volume":"32","author":"WM Hanna","year":"2019","unstructured":"Hanna WM, Parra-Herran C, Lu F-I, Slodkowska E, Rakovitch E, Nofech-Mozes S (2019) Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies. Mod Pathol 32:896\u2013915","journal-title":"Mod Pathol"},{"key":"5954_CR4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/A:1020399802795","volume":"7","author":"EY Lin","year":"2002","unstructured":"Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW (2002) The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 7:147\u2013162","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"5954_CR5","first-page":"53","volume":"44","author":"DC Colbert","year":"2005","unstructured":"Colbert DC, McGarry MP, O'Neill K, Lee NA, Lee JJ (2005) Decreased size and survival of weanling mice in litters of IL-5\u2013\/\u2013mice are a consequence of the IL-5 deficiency in nursing dams. Contemp Top Lab Anim Sci 44:53\u201355","journal-title":"Contemp Top Lab Anim Sci"},{"key":"5954_CR6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.devcel.2015.07.015","volume":"34","author":"V Plaks","year":"2015","unstructured":"Plaks V, Boldajipour B, Linnemann JR, Nguyen NH, Kersten K (2015) Adaptive immune regulation of mammary postnatal organogenesis. Dev Cell 34:493\u2013504","journal-title":"Dev Cell"},{"key":"5954_CR7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CRG Del Alcazar","year":"2017","unstructured":"Del Alcazar CRG, Huh SJ, Ekram MB, Trinh A, Liu LL (2017) Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov 7:1098\u20131115","journal-title":"Cancer Discov"},{"key":"5954_CR8","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2128","volume":"10","author":"RM Tamimi","year":"2008","unstructured":"Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67","journal-title":"Breast Cancer Res"},{"key":"5954_CR9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0046-8177(92)90257-4","volume":"23","author":"DC Allred","year":"1992","unstructured":"Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ (1992) Overexpression of HER-2\/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathol 23:974\u2013979","journal-title":"Human Pathol"},{"key":"5954_CR10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492\u20132502","journal-title":"JAMA"},{"key":"5954_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A (2016) The immune microenvironment of breast ductal carcinoma in situ. Modern Pathol 29:249","journal-title":"Modern Pathol"},{"issue":"5","key":"5954_CR12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ajcp\/aqz088","volume":"152","author":"E Vaziri Fard","year":"2019","unstructured":"Vaziri Fard E, Ali Y, Wang XI, Saluja K, Covinsky MH, Wang L, Zhang S (2019) Tumor-infiltrating lymphocyte volume is a better predictor of disease-free survival than stromal tumor-infiltrating lymphocytes in invasive breast Carcinoma. Am J Clin Pathol 152(5):656\u2013665","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"5954_CR13","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"A Seo","year":"2013","unstructured":"Seo A, Lee H, Kim E, Kim H, Jang M, Lee H, Kim YJ, Kim JH, Park SY (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109(10):2705\u20132713","journal-title":"Br J Cancer"},{"issue":"1","key":"5954_CR14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4(1):59","journal-title":"J Immunother Cancer"},{"issue":"5","key":"5954_CR15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0039-6060(03)00292-7","volume":"134","author":"SN Georgiannos","year":"2003","unstructured":"Georgiannos SN, Renaut A, Goode AW, Sheaff M (2003) The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 134(5):827\u2013834","journal-title":"Surgery"},{"issue":"3","key":"5954_CR16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0960-9776(03)00004-3","volume":"12","author":"S Vgenopoulou","year":"2003","unstructured":"Vgenopoulou S, Lazaris AC, Markopoulos C, Boltetsou E, Kyriakou V, Kavantzas N, Patsouris E, Davaris PS (2003) Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. The Breast 12(3):172\u2013178","journal-title":"The Breast"},{"issue":"6","key":"5954_CR17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.14055","volume":"76","author":"AA Thike","year":"2020","unstructured":"Thike AA, Chen X, Koh VCY, Binte Md Nasir ND, Yeong JP, Bay BH, Tan PH (2020) Higher densities of tumour-infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast. Histopathology 76(6):852\u2013864","journal-title":"Histopathology"},{"issue":"34","key":"5954_CR18","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373\u20135380","journal-title":"J Clin Oncol"},{"issue":"1","key":"5954_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-019-1178-0","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY (2020) Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res 22(1):1\u201312","journal-title":"Breast Cancer Res"},{"key":"5954_CR20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","volume":"161","author":"MJ Campbell","year":"2017","unstructured":"Campbell MJ, Baehner F, O\u2019Meara T, Ojukwu E, Han B (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17\u201328","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"5954_CR21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","volume":"129","author":"JS Yi","year":"2010","unstructured":"Yi JS, Cox MA, Zajac AJ (2010) T-cell exhaustion: characteristics, causes and conversion. Immunology 129(4):474\u2013481","journal-title":"Immunology"},{"key":"5954_CR22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cell.2007.04.034","volume":"129","author":"T Zuo","year":"2007","unstructured":"Zuo T, Wang L, Morrison C, Chang X, Zhang H (2007) FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2\/ErbB2 oncogene. Cell 129:1275\u20131286","journal-title":"Cell"},{"issue":"20","key":"5954_CR23","doi-asserted-by":"crossref","first-page":"33159","DOI":"10.18632\/oncotarget.16565","volume":"8","author":"ASS Khaja","year":"2017","unstructured":"Khaja ASS, Toor SM, El Salhat H, Faour I, Haq NU, Ali BR, Elkord E (2017) Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget 8(20):33159","journal-title":"Oncotarget"},{"key":"5954_CR24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-013-2556-4","volume":"139","author":"A Lal","year":"2013","unstructured":"Lal A, Chan L, DeVries S, Chin K, Scott GK (2013) FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 139:381\u2013390","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5954_CR25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/02841860701233443","volume":"46","author":"S Gupta","year":"2007","unstructured":"Gupta S, Joshi K, Wig J, Arora SK (2007) Intratumoral FOXP3 expression in infiltrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. Acta Oncol 46(6):792\u2013797","journal-title":"Acta Oncol"},{"issue":"4","key":"5954_CR26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3892\/mco.2013.107","volume":"1","author":"M Takenaka","year":"2013","unstructured":"Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi H (2013) FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 1(4):625\u2013632","journal-title":"Mol Clin Oncol"},{"key":"5954_CR27","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ejso.2017.01.011","volume":"43","author":"F Qian","year":"2017","unstructured":"Qian F, Qingping Y, Linquan W, Rongshou W, Shanshan R (2017) High tumor-infiltrating FoxP3+ T cells predict poor survival in estrogen receptor-positive breast cancer: a meta-analysis. Eur J Surg Oncol 43:1258\u20131264","journal-title":"Eur J Surg Oncol"},{"key":"5954_CR28","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.21873\/anticanres.14173","volume":"40","author":"R Fukui","year":"2020","unstructured":"Fukui R, Fujimoto Y, Watanabe T, Inoue N et al (2020) Association between FOXP3\/CD8 lymphocyte ratios and tumor infiltrating lymphocyte levels in different breast cancer subtypes. Anticancer Res 40:2141\u20132150","journal-title":"Anticancer Res"},{"issue":"19","key":"5954_CR29","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.7150\/jca.21030","volume":"8","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Shao N, Aierken N, Xie C, Ye R, Qian X, Hu Z, Zhang J, Lin Y (2017) Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis. J Cancer 8(19):4098","journal-title":"J Cancer"},{"issue":"1","key":"5954_CR30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/0284186X.2012.731520","volume":"52","author":"S Lee","year":"2013","unstructured":"Lee S, Cho EY, Park YH, Ahn JS, Im Y-H (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52(1):73\u201381","journal-title":"Acta Oncol"},{"issue":"10","key":"5954_CR31","doi-asserted-by":"crossref","first-page":"e1218106","DOI":"10.1080\/2162402X.2016.1218106","volume":"5","author":"M Semeraro","year":"2016","unstructured":"Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N (2016) The ratio of CD8+\/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology 5(10):e1218106","journal-title":"Oncoimmunology"},{"issue":"8","key":"5954_CR32","first-page":"5039","volume":"11","author":"G-L Peng","year":"2019","unstructured":"Peng G-L, Li L, Guo Y-W, Yu P, Yin X-J, Wang S, Liu C-P (2019) CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer. Ame J transl 11(8):5039","journal-title":"Ame J transl"},{"key":"5954_CR33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13058-014-0432-8","volume":"16","author":"S Liu","year":"2014","unstructured":"Liu S, Foulkes WD, Leung S, Gao D, Lau S (2014) Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 16:432","journal-title":"Breast Cancer Res"},{"key":"5954_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-017-4161-4","volume":"163","author":"J Yeong","year":"2017","unstructured":"Yeong J, Thike AA, Lim JCT, Lee B, Li H (2017) Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat 163:21\u201335","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5954_CR35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","volume":"130","author":"F Liu","year":"2011","unstructured":"Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L (2011) CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130(2):645\u2013655","journal-title":"Breast Cancer Res Treat"},{"key":"5954_CR36","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3389\/fimmu.2018.02605","volume":"9","author":"DP Saraiva","year":"2018","unstructured":"Saraiva DP, Jacinto A, Borralho P, Braga S, Cabral MG (2018) HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy. Front immunol 9:2605","journal-title":"Front immunol"},{"key":"5954_CR37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000086659","volume":"86","author":"W Holtmeier","year":"2005","unstructured":"Holtmeier W, Kabelitz D (2005) \u03b3\u03b4 T cells link innate and adaptive immune responses. Chem Immunol Allergy 86:151\u2013183","journal-title":"Chem Immunol Allergy"},{"issue":"1","key":"5954_CR38","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.4110\/in.2020.20.e5","volume":"20","author":"HW Lee","year":"2020","unstructured":"Lee HW, Chung YS, Kim TJ (2020) Heterogeneity of human \u03b3\u03b4 T cells and their role in cancer immunity. Immune Netw 20(1):e5","journal-title":"Immune Netw"},{"issue":"3","key":"5954_CR39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/cmi.2016.55","volume":"14","author":"D Wu","year":"2017","unstructured":"Wu D, Wu P, Qiu F, Wei Q, Huang J (2017) Human \u03b3\u03b4T-cell subsets and their involvement in tumor immunity. Cell Mol Immunol 14(3):245\u2013253","journal-title":"Cell Mol Immunol"},{"key":"5954_CR40","first-page":"10","volume":"10","author":"S Dhar","year":"2010","unstructured":"Dhar S, Chiplunkar SV (2010) Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by V\u03b39V\u03b42 T cells. Cancer Immunol 10:10","journal-title":"Cancer Immunol"},{"issue":"2","key":"5954_CR41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","volume":"27","author":"G Peng","year":"2007","unstructured":"Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF (2007) Tumor-infiltrating \u03b3\u03b4 T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27(2):334\u2013348","journal-title":"Immunity"},{"key":"5954_CR42","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.4049\/jimmunol.1201892","volume":"189","author":"C Ma","year":"2012","unstructured":"Ma C, Zhang Q, Ye J, Wang F, Zhang Y (2012) Tumor-infiltrating \u03b3\u03b4 T lymphocytes predict clinical outcome in human breast cancer. J Immunol 189:5029\u20135036","journal-title":"J Immunol"},{"key":"5954_CR43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3389\/fimmu.2017.01041","volume":"8","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Tu W (2017) Dual face of V\u03b39V\u03b42-T cells in tumor immunology: anti-versus pro-tumoral activities. Front immunol 8:1041","journal-title":"Front immunol"},{"key":"5954_CR44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K (2015) IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522:345","journal-title":"Nature"},{"key":"5954_CR45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Med 21:938","journal-title":"Nature Med"},{"key":"5954_CR46","doi-asserted-by":"crossref","first-page":"e26066","DOI":"10.4161\/onci.26066","volume":"2","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Willard-Gallo K (2013) Tumor-infiltrating follicular helper T cells: the new kids on the block. Oncoimmunology 2:e26066","journal-title":"Oncoimmunology"},{"key":"5954_CR47","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fimmu.2017.01412","volume":"8","author":"C Solinas","year":"2017","unstructured":"Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G (2017) Immune checkpoint molecules on tumor-infiltrating lymphocytes and their association with tertiary lymphoid structures in human breast cancer. Front Immunol 8:1412","journal-title":"Front Immunol"},{"key":"5954_CR48","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M (2013) CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123:2873\u20132892","journal-title":"J Clin Invest"},{"key":"5954_CR49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4143\/crt.2016.215","volume":"49","author":"IH Song","year":"2017","unstructured":"Song IH, Heo S-H, Bang WS, Park HS, Park IA (2017) Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer. Cancer Res Treat 49:399","journal-title":"Cancer Res Treat"},{"issue":"11","key":"5954_CR50","doi-asserted-by":"crossref","first-page":"e91487","DOI":"10.1172\/jci.insight.91487","volume":"2","author":"C Gu-Trantien","year":"2017","unstructured":"Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Broh\u00e9e S, Garaud S et al (2017) CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI insight 2(11):e91487","journal-title":"JCI insight"},{"key":"5954_CR51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12013-011-9276-3","volume":"62","author":"L Yang","year":"2012","unstructured":"Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B (2012) Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys 62:153\u2013159","journal-title":"Cell Biochem Biophys"},{"key":"5954_CR52","doi-asserted-by":"crossref","first-page":"e1055444","DOI":"10.1080\/2162402X.2015.1055444","volume":"5","author":"M Thibaudin","year":"2016","unstructured":"Thibaudin M, Chaix M, Boidot R, V\u00e9gran F, Derang\u00e8re V (2016) Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology 5:e1055444","journal-title":"Oncoimmunology"},{"issue":"2","key":"5954_CR53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/his.12156","volume":"63","author":"WC Chen","year":"2013","unstructured":"Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH (2013) Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 63(2):225\u2013233","journal-title":"Histopathology"},{"issue":"9","key":"5954_CR54","doi-asserted-by":"crossref","first-page":"e1624130","DOI":"10.1080\/2162402X.2019.1624130","volume":"8","author":"L Faucheux","year":"2019","unstructured":"Faucheux L, Grandclaudon M, Perrot-Dock\u00e8s M, Sirven P, Berger F, Hamy A, Fourchotte V, Vincent-Salomon A, Mechta-Grigoriou F, Reyal F (2019) A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. OncoImmunology 8(9):e1624130","journal-title":"OncoImmunology"},{"issue":"6","key":"5954_CR55","first-page":"5475","volume":"15","author":"Z Lv","year":"2018","unstructured":"Lv Z, Liu M, Shen J, Xiang D, Ma Y, Ji Y (2018) Association of serum interleukin-10, interleukin-17A and transforming growth factor-\u03b1 levels with human benign and malignant breast diseases. Ex Ther Med 15(6):5475\u20135480","journal-title":"Ex Ther Med"},{"issue":"3","key":"5954_CR56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10238-019-00559-6","volume":"19","author":"G Avalos-Navarro","year":"2019","unstructured":"Avalos-Navarro G, Mu\u00f1oz-Valle JF, Daneri-Navarro A, Quintero-Ramos A et al (2019) Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile. Clin Exp Med 19(3):385\u2013391","journal-title":"Clin Exp Med"},{"issue":"1","key":"5954_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"Y Li","year":"2019","unstructured":"Li Y, Wang Y, Shi Z, Liu J, Zheng S, Yang J et al (2019) clinicopathological and prognostic Role of STAT3\/p-STAT3 in breast cancer patients in China: a meta-analysis. Sci Rep 9(1):1\u20139","journal-title":"Sci Rep"},{"key":"5954_CR58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10911-009-9124-x","volume":"14","author":"S Pensa","year":"2009","unstructured":"Pensa S, Watson CJ, Poli V (2009) Stat3 and the inflammation\/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia 14:121\u2013129","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"19","key":"5954_CR59","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/s41388-018-0132-4","volume":"37","author":"SR Sirkisoon","year":"2018","unstructured":"Sirkisoon SR, Carpenter RL, Rimkus T, Anderson A, Harrison A et al (2018) Interaction between STAT3 and GLI1\/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37(19):2502\u20132514","journal-title":"Oncogene"},{"issue":"1","key":"5954_CR60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-016-3709-z","volume":"156","author":"MA Aleskandarany","year":"2016","unstructured":"Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A et al (2016) The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast Cancer Res Treat 156(1):9\u201320","journal-title":"Breast Cancer Res Treat"},{"key":"5954_CR61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ebiom.2016.02.028","volume":"6","author":"TG Oh","year":"2016","unstructured":"Oh TG, Wang S-CM, Acharya BR, Goode JM, Graham JD (2016) The nuclear receptor, ROR\u03b3, regulates pathways necessary for breast cancer metastasis. EbioMedicine 6:59\u201372","journal-title":"EbioMedicine"},{"key":"5954_CR62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1210\/me.2012-1265","volume":"27","author":"GE Muscat","year":"2013","unstructured":"Muscat GE, Eriksson NA, Byth K, Loi S, Graham D (2013) Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol 27:350\u2013365","journal-title":"Mol Endocrinol"},{"key":"5954_CR63","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/eji.201242951","volume":"43","author":"L Benevides","year":"2013","unstructured":"Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS (2013) Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 43:1518\u20131528","journal-title":"Eur J Immunol"},{"issue":"8","key":"5954_CR64","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","volume":"14","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria A, Madrigal JA, Saudemont A (2017) B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 14(8):662\u2013674","journal-title":"Cell Mol Immunol"},{"key":"5954_CR65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","volume":"132","author":"S Mahmoud","year":"2012","unstructured":"Mahmoud S, Lee A, Paish E, Macmillan R, Ellis I (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132:545\u2013553","journal-title":"Breast Cancer Res Treat"},{"key":"5954_CR66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/his.13217","volume":"71","author":"I Miligy","year":"2017","unstructured":"Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC (2017) Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology 71:258\u2013268","journal-title":"Histopathology"},{"key":"5954_CR67","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2018.00470","volume":"9","author":"M Shen","year":"2018","unstructured":"Shen M, Wang J, Ren X (2018) New insights into tumor-infiltrating B lymphocytes in breast cancer: clinical impacts and regulatory mechanisms. Front Immunol 9:470","journal-title":"Front Immunol"},{"key":"5954_CR68","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3389\/fimmu.2018.01209","volume":"9","author":"J Yeong","year":"2018","unstructured":"Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, Lye WK, Putti TC, Dent R, Lim E (2018) High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front immunol 9:1209","journal-title":"Front immunol"},{"key":"5954_CR69","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5301\/tj.5000624","volume":"104","author":"Y Xu","year":"2018","unstructured":"Xu Y, Lan S, Zheng Q (2018) Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast. Tumori 104:196\u2013201","journal-title":"Tumori"},{"key":"5954_CR70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0377-4929.118676","volume":"56","author":"TE Helal","year":"2013","unstructured":"Helal TE, Ibrahim EA, Alloub AI (2013) Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian J Pathol Microbiol 56:89","journal-title":"Indian J Pathol Microbiol"},{"key":"5954_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129641","author":"S Garaud","year":"2019","unstructured":"Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx J-N, Boisson A, Duvillier H (2019) Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.129641","journal-title":"JCI Insight"},{"key":"5954_CR72","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3109\/0284186X.2011.652737","volume":"51","author":"B L\u00f6fdahl","year":"2012","unstructured":"L\u00f6fdahl B, Ahlin C, Holmqvist M, Holmberg L, Zhou W (2012) Inflammatory cells in node-negative breast cancer. Acta Oncol 51:680\u2013686","journal-title":"Acta Oncol"},{"key":"5954_CR73","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","volume":"71","author":"PB Olkhanud","year":"2011","unstructured":"Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 71:3505\u20133515","journal-title":"Cancer Res"},{"issue":"8","key":"5954_CR74","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1158\/0008-5472.CAN-12-3450","volume":"73","author":"S Lindner","year":"2013","unstructured":"Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, Beyer T, Reister F, Fabricius D, Lotfi R (2013) Interleukin 21\u2013induced granzyme B\u2013expressing B cells infiltrate tumors and regulate T cells. Cancer Res 73(8):2468\u20132479","journal-title":"Cancer Res"},{"issue":"5","key":"5954_CR75","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/bjc.2012.347","volume":"107","author":"ZM Mohammed","year":"2012","unstructured":"Mohammed ZM, Going J, Edwards J, Elsberger B, Doughty J, McMillan D (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5):864","journal-title":"Br J Cancer"},{"key":"5954_CR76","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol 11:889","journal-title":"Nature Immunol"},{"key":"5954_CR77","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/bjc.2013.493","volume":"109","author":"Z Mohammed","year":"2013","unstructured":"Mohammed Z, Going J, Edwards J, Elsberger B, McMillan D (2013) The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 109:1676","journal-title":"Br J Cancer"},{"key":"5954_CR78","doi-asserted-by":"crossref","first-page":"111932","DOI":"10.1016\/j.yexcr.2020.111932","volume":"4","author":"FB Gunnarsd\u00f3ttir","year":"2020","unstructured":"Gunnarsd\u00f3ttir FB, Hagerling C, Bergenfelz C, Mehmeti M et al (2020) Inflammatory macrophage derived TNF\u03b1 downregulates estrogen receptor \u03b1 via FOXO3a inactivation in human breast cancer cells. Exp Cell Res 4:111932","journal-title":"Exp Cell Res"},{"key":"5954_CR79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","volume":"17","author":"S Sousa","year":"2015","unstructured":"Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J (2015) Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res 17:101","journal-title":"Breast Cancer Res"},{"key":"5954_CR80","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/his.12607","volume":"66","author":"S Tiainen","year":"2015","unstructured":"Tiainen S, Tumelius R, Rilla K, H\u00e4m\u00e4l\u00e4inen K, Tammi M (2015) High numbers of macrophages, especially M2-like (CD 163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66:873\u2013883","journal-title":"Histopathology"},{"key":"5954_CR81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2017.09.035","volume":"222","author":"WJ Zhang","year":"2018","unstructured":"Zhang WJ, Wang XH, Gao ST, Chen C, Xu XY (2018) Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res 222:93\u2013101","journal-title":"J Surg Res"},{"key":"5954_CR82","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1002\/cti2.1108","volume":"9","author":"RN Ramos","year":"2010","unstructured":"Ramos RN, Rodriguez C, Hubert M, Ardin M et al (2010) CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clin Transl Immunol 9:e1108","journal-title":"Clin Transl Immunol"},{"key":"5954_CR83","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood.V81.6.1607.1607","volume":"81","author":"CL Holness","year":"1993","unstructured":"Holness CL, Simmons DL (1993) Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81:1607\u20131613","journal-title":"Blood"},{"key":"5954_CR84","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/cas.13287","volume":"108","author":"Y Miyasato","year":"2017","unstructured":"Miyasato Y, Shiota T, Ohnishi K, Pan C, Yano H (2017) High density of CD 204-positive macrophages predicts worse clinical prognosis in patients with breast cancer. Cancer Sci 108:1693\u20131700","journal-title":"Cancer Sci"},{"key":"5954_CR85","doi-asserted-by":"crossref","first-page":"34758","DOI":"10.18632\/oncotarget.5325","volume":"6","author":"L Lin","year":"2015","unstructured":"Lin L, Chen YS, Yao YD, Chen JQ, Chen JN (2015) CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget 6:34758","journal-title":"Oncotarget"},{"key":"5954_CR86","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2147\/OTT.S61838","volume":"7","author":"ZY Yuan","year":"2014","unstructured":"Yuan ZY, Luo RZ, Peng RJ, Wang SS, Xue C (2014) High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets Ther 7:1475","journal-title":"OncoTargets Ther"},{"key":"5954_CR87","doi-asserted-by":"crossref","first-page":"e0125728","DOI":"10.1371\/journal.pone.0125728","volume":"10","author":"JM Gwak","year":"2015","unstructured":"Gwak JM, Jang MH, Kim DI, Seo AN, Park SY (2015) Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS One 10:e0125728","journal-title":"PLoS One"},{"key":"5954_CR88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41467-017-02481-5","volume":"9","author":"N Linde","year":"2018","unstructured":"Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E et al (2018) Macrophages orchestrate breast cancer early dissemination and metastasis. Nature Commun 9:21","journal-title":"Nature Commun"},{"issue":"1","key":"5954_CR89","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek C, Pont\u00e9n F, Jirstr\u00f6m K, Leandersson K (2012) The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12(1):306","journal-title":"BMC Cancer"},{"issue":"2","key":"5954_CR90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jclinpath-2011-200355","volume":"65","author":"S Mahmoud","year":"2012","unstructured":"Mahmoud S, Lee A, Paish E, Macmillan R, Ellis I, Green A (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159\u2013163","journal-title":"J Clin Pathol"},{"issue":"3","key":"5954_CR91","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00428-012-1362-4","volume":"462","author":"ES Ch\u2019ng","year":"2013","unstructured":"Ch\u2019ng ES, Sharif SET, Jaafar H (2013) In human invasive breast ductal carcinoma, tumor stromal macrophages and tumor nest macrophages have distinct relationships with clinicopathological parameters and tumor angiogenesis. Virchows Archiv 462(3):257\u2013267","journal-title":"Virchows Archiv"},{"issue":"7","key":"5954_CR92","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-08-2179","volume":"15","author":"BD Robinson","year":"2009","unstructured":"Robinson BD, Sica GL, Liu Y-F, Rohan TE, Gertler FB, Condeelis JS, Jones JG (2009) Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15(7):2433\u20132441","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5954_CR93","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-06-1823","volume":"67","author":"JB Wyckoff","year":"2007","unstructured":"Wyckoff JB, Wang Y, Lin EY, Li J-f, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67(6):2649\u20132656","journal-title":"Cancer Res"},{"issue":"5","key":"5954_CR94","first-page":"1326","volume":"62","author":"RD Leek","year":"2002","unstructured":"Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, Harris AL (2002) Relation of hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 62(5):1326\u20131329","journal-title":"Cancer Res"},{"issue":"20","key":"5954_CR95","first-page":"4625","volume":"56","author":"RD Leek","year":"1996","unstructured":"Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56(20):4625\u20134629","journal-title":"Cancer Res"},{"key":"5954_CR96","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-019-05336-3","volume":"177","author":"J Zeindler","year":"2019","unstructured":"Zeindler J, Angehrn F, Droeser R et al (2019) Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer. Breast Cancer Res Treat 177:581\u2013589","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"5954_CR97","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1158\/0008-5472.CAN-05-1734","volume":"65","author":"MM Queen","year":"2005","unstructured":"Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL (2005) Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 65(19):8896\u20138904","journal-title":"Cancer Res"},{"issue":"6","key":"5954_CR98","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-15-1157","volume":"6","author":"A Spiegel","year":"2016","unstructured":"Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M et al (2016) Neutrophils suppress intraluminal NK cell\u2013mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov 6(6):630\u2013649","journal-title":"Cancer Discov"},{"key":"5954_CR99","doi-asserted-by":"crossref","first-page":"e1134073","DOI":"10.1080\/2162402X.2015.1134073","volume":"5","author":"M Demers","year":"2016","unstructured":"Demers M, Wong SL, Martinod K, Gallant M, Cabral JE (2016) Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology 5:e1134073","journal-title":"Oncoimmunology"},{"key":"5954_CR100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/febs.14206","volume":"285","author":"KA Mouchemore","year":"2018","unstructured":"Mouchemore KA, Anderson RL, Hamilton JA (2018) Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J 285:665\u2013679","journal-title":"FEBS J"},{"key":"5954_CR101","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-015-0535-8","volume":"13","author":"C Verma","year":"2015","unstructured":"Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M (2015) Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med 13:180","journal-title":"J Transl Med"},{"issue":"2","key":"5954_CR102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","volume":"11","author":"Z Liu","year":"2018","unstructured":"Liu Z, Li M, Jiang Z, Wang X (2018) A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol 11(2):311\u2013329","journal-title":"Transl Oncol"},{"issue":"9","key":"5954_CR103","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","volume":"121","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J et al (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121(9):3609\u20133622","journal-title":"J Clin Invest"},{"key":"5954_CR104","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.4049\/jimmunol.1301889","volume":"192","author":"P Carrega","year":"2014","unstructured":"Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P (2014) CD56 bright perforin low noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol 192:3805\u20133815","journal-title":"J Immunol"},{"key":"5954_CR105","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.7314\/APJCP.2014.15.8.3757","volume":"15","author":"AS Rathore","year":"2014","unstructured":"Rathore AS, Goel MM, Makker A, Kumar S, Srivastava AN (2014) Is the tumor infiltrating natural killer cell (NK-TILs) count in infiltrating ductal carcinoma of breast prognostically significant. Asian Pac J Cancer Prev 15:3757\u20133761","journal-title":"Asian Pac J Cancer Prev"},{"key":"5954_CR106","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1084\/jem.20061120","volume":"204","author":"C Aspord","year":"2007","unstructured":"Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC (2007) Breast cancer instructs dendritic cells to prime interleukin 13\u2013secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037\u20131047","journal-title":"J Exp Med"},{"key":"5954_CR107","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ijc.10915","volume":"104","author":"M Iwamoto","year":"2003","unstructured":"Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H (2003) Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104:92\u201397","journal-title":"Int J Cancer"},{"key":"5954_CR108","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 2:1096","journal-title":"Nature Med"},{"key":"5954_CR109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","volume":"140","author":"J Markowitz","year":"2013","unstructured":"Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE (2013) Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 140:13\u201321","journal-title":"Breast Cancer Res Treat"},{"key":"5954_CR110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"5954_CR111","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1074\/jbc.M112.441402","volume":"288","author":"LM Hix","year":"2013","unstructured":"Hix LM, Karavitis J, Khan MW, Shi YH, Khazaie K, Zhang M (2013) Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem 288(17):11676\u201311688","journal-title":"J Biol Chem"},{"key":"5954_CR112","doi-asserted-by":"crossref","first-page":"e1002194","DOI":"10.1371\/journal.pmed.1002194","volume":"13","author":"HR Ali","year":"2016","unstructured":"Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C (2016) Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med 13:e1002194","journal-title":"PLoS Med"},{"key":"5954_CR113","doi-asserted-by":"crossref","first-page":"e1002330","DOI":"10.1371\/journal.pbio.1002330","volume":"13","author":"D Gallego-Ortega","year":"2015","unstructured":"Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A (2015) ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells. PLoS Biol 13:e1002330","journal-title":"PLoS Biol"},{"key":"5954_CR114","doi-asserted-by":"crossref","first-page":"e1001461","DOI":"10.1371\/journal.pbio.1001461","volume":"10","author":"M Kalyuga","year":"2012","unstructured":"Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ (2012) ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol 10:e1001461","journal-title":"PLoS Biol"},{"key":"5954_CR115","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1172\/JCI99673","volume":"128","author":"S Kumar","year":"2018","unstructured":"Kumar S, Wilkes DW, Samuel N, Blanco MA, Nayak A (2018) \u0394Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J Clin Invest 128:5095\u20135109","journal-title":"J Clin Invest"},{"key":"5954_CR116","doi-asserted-by":"crossref","first-page":"114554","DOI":"10.18632\/oncotarget.23020","volume":"8","author":"H Zhu","year":"2017","unstructured":"Zhu H, Gu Y, Xue Y, Yuan M, Cao X, Liu Q (2017) CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. Oncotarget 8:114554","journal-title":"Oncotarget"},{"key":"5954_CR117","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nm.3892","volume":"21","author":"GF Sonnenberg","year":"2015","unstructured":"Sonnenberg GF, Artis D (2015) Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nature Med 21:698","journal-title":"Nature Med"},{"key":"5954_CR118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coi.2015.01.004","volume":"32","author":"VS Cortez","year":"2015","unstructured":"Cortez VS, Robinette ML, Colonna M (2015) Innate lymphoid cells: new insights into function and development. Curr Opin Immunol 32:71\u201377","journal-title":"Curr Opin Immunol"},{"key":"5954_CR119","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12885-018-4262-4","volume":"18","author":"M Salimi","year":"2018","unstructured":"Salimi M, Wang R, Yao X, Li X, Wang X (2018) Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer 18:341","journal-title":"BMC Cancer"},{"key":"5954_CR120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijc.29443","volume":"138","author":"Z Tian","year":"2016","unstructured":"Tian Z, van Velkinburgh JC, Wu Y, Ni B (2016) Innate lymphoid cells involve in tumorigenesis. Int J Cancer 138:22\u201329","journal-title":"Int J Cancer"},{"key":"5954_CR121","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ijc.28481","volume":"134","author":"IP Jovanovic","year":"2014","unstructured":"Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ (2014) Interleukin-33\/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 134:1669\u20131682","journal-title":"Int J Cancer"},{"key":"5954_CR122","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.1158\/0008-5472.CAN-09-2100","volume":"69","author":"T Fujisawa","year":"2009","unstructured":"Fujisawa T, Joshi B, Nakajima A, Puri RK (2009) A novel role of interleukin-13 receptor \u03b12 in pancreatic cancer invasion and metastasis. Cancer Res 69:8678\u20138685","journal-title":"Cancer Res"},{"key":"5954_CR123","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/0008-5472.CAN-16-0598","volume":"77","author":"S Irshad","year":"2017","unstructured":"Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R (2017) ROR\u03b3t+ innate lymphoid cells promote lymph node metastasis of breast cancers. Cancer Res 77:1083\u20131096","journal-title":"Cancer Res"},{"key":"5954_CR124","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1200\/jco.2014.32.15_suppl.11082","volume":"32","author":"S Irshad","year":"2014","unstructured":"Irshad S, Lawler K, Flores-Borja F, Monypenny J, Evans R (2014) Effect of lymphoid tissue inducer cells on lymphatic tumor cell invasion via activation of the RANKL\/RANK axis within triple-negative breast cancers. J Clin Oncol 32:11082","journal-title":"J Clin Oncol"},{"key":"5954_CR125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4048\/jbc.2018.21.2.124","volume":"21","author":"Y Wang","year":"2018","unstructured":"Wang Y, Dong T, Xuan Q, Zhao H, Qin L, Zhang Q (2018) Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer. J Breast Cancer 21:124\u2013133","journal-title":"J Breast Cancer"},{"issue":"5","key":"5954_CR126","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/path.5406","volume":"250","author":"PI Gonzalez-Ericsson","year":"2020","unstructured":"Gonzalez-Ericsson PI, Stovgaard ES, Sua LF et al (2020) The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol 250(5):667\u2013684","journal-title":"J Pathol"},{"key":"5954_CR127","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13578-018-0232-4","volume":"8","author":"F Tang","year":"2018","unstructured":"Tang F, Zheng P (2018) Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1\/PD-L1 blockade mediated cancer immunotherapy? Cell Biosci 8:34","journal-title":"Cell Biosci"},{"key":"5954_CR128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-019-05371-0","volume":"178","author":"W Huang","year":"2019","unstructured":"Huang W, Ran R, Shao B et al (2019) Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat 178:17\u201333","journal-title":"Breast Cancer Res Treat"},{"key":"5954_CR129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","volume":"146","author":"S Muenst","year":"2014","unstructured":"Muenst S, Schaerli A, Gao F, D\u00e4ster S, Trella E (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 146:15\u201324","journal-title":"Breast Cancer Res Treat"},{"key":"5954_CR130","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/CAD.0000000000000683","volume":"29","author":"T Zhou","year":"2018","unstructured":"Zhou T, Xu D, Tang B, Ren Y, Han Y (2018) Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis. Anticancer Drugs 29:904","journal-title":"Anticancer Drugs"},{"key":"5954_CR131","first-page":"8505021","volume":"2019","author":"Q Song","year":"2019","unstructured":"Song Q, Shi F, Adair M, Chang H, Guan X (2019) Cell counts, rather than proportion, of CD8\/PD-1 tumor-infiltrating lymphocytes in a tumor microenvironment associated with pathological characteristics of Chinese invasive ductal breast cancer. J Immunol Res 2019:8505021","journal-title":"J Immunol Res"},{"key":"5954_CR132","doi-asserted-by":"crossref","first-page":"e0195958","DOI":"10.1371\/journal.pone.0195958","volume":"13","author":"A Kassardjian","year":"2018","unstructured":"Kassardjian A, Shintaku PI, Moatamed NA (2018) Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PLoS One 13:e0195958","journal-title":"PLoS One"},{"key":"5954_CR133","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00262-015-1696-2","volume":"64","author":"H Yu","year":"2015","unstructured":"Yu H, Yang J, Jiao S, Li Y, Zhang W, Wang J (2015) Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol Immunother 64:853\u2013860","journal-title":"Cancer Immunol Immunother"},{"key":"5954_CR134","first-page":"5093","volume":"15","author":"G Lan","year":"2018","unstructured":"Lan G, Li J, Wen Q, Lin L, Chen L (2018) Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. Oncology Lett 15:5093\u20135097","journal-title":"Oncology Lett"},{"key":"5954_CR135","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML (2016) Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2:1354\u20131360","journal-title":"JAMA Oncol"},{"key":"5954_CR136","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2005.04.015","volume":"235","author":"F Triebel","year":"2006","unstructured":"Triebel F, Hacene K, Pichon M-F (2006) A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 235:147\u2013153","journal-title":"Cancer Lett"},{"key":"5954_CR137","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/annonc\/mdx557","volume":"28","author":"S Burugu","year":"2017","unstructured":"Burugu S, Gao D, Leung S, Chia S, Nielsen T (2017) LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1\/PD-L1+ tumors. Ann Oncol 28:2977\u20132984","journal-title":"Ann Oncol"},{"key":"5954_CR138","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989\u20131004","journal-title":"Immunity"},{"key":"5954_CR139","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH (2016) Coinhibitory pathways in immunotherapy for cancer. Ann Rev Immunol 34:539\u2013573","journal-title":"Ann Rev Immunol"},{"key":"5954_CR140","doi-asserted-by":"crossref","first-page":"106113","DOI":"10.1016\/j.intimp.2019.106113","volume":"78","author":"H Du","year":"2020","unstructured":"Du H, Yi Z, Wang L, Li Z et al (2020) The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. Int Immunopharmacol 78:106113","journal-title":"Int Immunopharmacol"},{"key":"5954_CR141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-016-0783-4","volume":"18","author":"G Bottai","year":"2016","unstructured":"Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C (2016) An immune stratification reveals a subset of PD-1\/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res 18:121","journal-title":"Breast Cancer Res"},{"key":"5954_CR142","doi-asserted-by":"crossref","first-page":"e1502128","DOI":"10.1080\/2162402X.2018.1502128","volume":"7","author":"S Burugu","year":"2018","unstructured":"Burugu S, Gao D, Leung S, Chia SK, Nielsen TO (2018) TIM-3 expression in breast cancer. Oncoimmunology 7:e1502128","journal-title":"Oncoimmunology"},{"key":"5954_CR143","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3892\/mco.2017.1360","volume":"7","author":"H Zhang","year":"2017","unstructured":"Zhang H, Xiang R, Wu B, Li J, Luo G (2017) T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes. Mol Clin Oncol 7:557\u2013563","journal-title":"Mol Clin Oncol"},{"key":"5954_CR144","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4048\/jbc.2018.21.e61","volume":"21","author":"KD Byun","year":"2018","unstructured":"Byun KD, Hwang HJ, Park KJ, Kim MC, Cho SH (2018) T-Cell Immunoglobulin mucin 3 expression on tumor infiltrating lymphocytes as a positive prognosticator in triple-negative breast cancer. J Breast Cancer 21:406\u2013414","journal-title":"J Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05954-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05954-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05954-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T20:17:15Z","timestamp":1696796235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05954-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,3]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5954"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05954-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,3]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MS declares that she has no conflict of interest. HM declares that he has no conflict of interest. NR has received research grant from Tehran University of Medical Sciences (Grant Number 41086).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}